USC.edu
Are You a Patient?

Mark Floyd Lew, MD

Professor of Clinical Neurology

Joseph P. Van Der Meulen, M.D. Chair in Parkinson's Disease Research in Honor of Robert J. Pasarow

Vice Chair, Department of Neurology

Division Chief, Movement Disorders

Image of Mark Floyd Lew, MD
Is this your profile? Click to edit
Phone +1 323 442 5728
Email [email protected]
CTSI Profile

Overview

Dr. Lew has an international reputation for the treatment of patients with Parkinson’s disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology. Dr. Lew is the director of the Division of Movement Disorders and serves as the vice chairman of the Department of Neurology. He has lectured extensively in the United States and abroad on clinical research related to new therapies for Parkinson’s disease and dystonia. Dr. Lew also collaborates closely with local and national advocacy organizations (e.g., the Hollyrod Foundation and the National Parkinson’s Foundation) to increase public awareness and to support research and care.

Research Funding

  • Neuroprotective Clinical Studies in Parkinson's Disease
    NIH · U10NS044462 · Sep 15, 2002 – Nov 30, 2015 · Role: Principal Investigator

Publications

  • The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease. Nat Aging. 2026 Mar; 6(3):626-635.. View in PubMed
  • A novel mutation in colony-stimulating factor 1 receptor (CSF1R) causing CSF1R-related disorder (CSF1R-RD). Neurocase. 2026 Feb; 32(1):13-21.. View in PubMed
  • Underlying Tremor Improvement with Consistent Use of Transcutaneous Afferent Patterned Stimulation in Patients with Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2026; 16:1.. View in PubMed
  • Independent Associations of Sleep and Walking with Cognition in Parkinson’s Disease: A Perivascular Spaces Analysis. bioRxiv. 2025 Sep 29.. View in PubMed
  • Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial. Neurol Ther. 2025 Aug; 14(4):1553-1567.. View in PubMed
  • Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study. J Parkinsons Dis. 2025 Mar; 15(2):361-373.. View in PubMed
  • Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel. Clin Park Relat Disord. 2024; 11:100264.. View in PubMed
  • Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasets. Commun Biol. 2024 02 17; 7(1):200.. View in PubMed
  • BoNT clinical trial update: Sialorrhea. Toxicon. 2023 Apr; 226:107087.. View in PubMed
  • Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022; 7:100161. Isaacson SH, Pagan FL, Lew MF , Pahwa R . . View in PubMed

Similar People